Logo

ANVS

Annovis Bio, Inc.

ANVS

Annovis Bio, Inc. • NYSE
$5.10 ▲ 3.66% (+0.18)
Market Cap $100.34 M
52w High $7.39
52w Low $1.11
Dividend Yield 0%
P/E -3.57
Volume 1.28M
Outstanding Shares 19.67M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $7.435M ▲ $-7.263M ▼ 0% $-0.37 ▼ $-7.263M ▼
Q2-2025 $0 $6.271M ▼ $-6.22M ▼ 0% $-0.32 $-6.271M ▲
Q1-2025 $0 $6.283M ▼ $-5.537M ▲ 0% $-0.32 ▲ $-6.283M ▲
Q4-2024 $0 $6.735M ▲ $-5.865M ▲ 0% $-0.43 ▲ $-6.735M ▼
Q3-2024 $0 $4.388M $-12.638M 0% $-0.97 $-4.388M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $15.286M ▼ $17.189M ▼ $4.033M ▲ $13.156M ▼
Q2-2025 $17.13M ▼ $21.455M ▼ $3.124M ▲ $18.33M ▼
Q1-2025 $22.236M ▲ $26.737M ▲ $2.683M ▼ $24.054M ▲
Q4-2024 $10.552M ▼ $13.926M ▼ $4.618M ▼ $9.308M ▲
Q3-2024 $12.637M $14.362M $7.298M $7.064M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-7.263M ▼ $-3.488M ▲ $0 $1.644M ▲ $-1.844M ▲ $-3.488M ▲
Q2-2025 $-6.22M ▼ $-5.106M ▲ $0 $0 ▼ $-5.106M ▼ $-5.106M ▲
Q1-2025 $-5.537M ▲ $-8.099M ▲ $0 $19.783M ▲ $11.684M ▲ $-8.099M ▲
Q4-2024 $-5.865M ▲ $-8.285M ▼ $0 $6.201M ▼ $-2.085M ▼ $-8.285M ▼
Q3-2024 $-12.638M $-3.201M $0 $11.84M $8.639M $-3.201M

Five-Year Company Overview

Income Statement

Income Statement Annovis is still a pure R&D biotech with no product sales yet, so its income statement is driven almost entirely by research and overhead costs. Operating losses have been steady and typical for an early‑stage biotech, but the most recent year shows an exceptionally large net loss compared with prior years. That suggests a major one‑off charge, accounting adjustment, or financing‑related impact on the bottom line rather than a dramatic change in day‑to‑day operations. Overall, the business is pre‑revenue, loss‑making, and highly dependent on future funding and eventual drug approvals to change that picture.

Balance Sheet

Balance Sheet The balance sheet is very small and simple. Assets are modest and largely made up of cash, with essentially no traditional debt, which is a positive from a leverage standpoint. However, the equity base has swung around and at one point dipped negative, indicating accumulated losses and a thin capital cushion. This profile is typical for a small, clinical‑stage biotech: low fixed assets, no revenue‑backed collateral, and an ongoing need to raise fresh equity or partnerships to fund operations.

Cash Flow

Cash Flow Cash flows reflect a company that only spends money rather than bringing it in. Operating cash burn has been consistent over several years and then jumped sharply in the latest period, likely tied to ramped‑up clinical activity or a specific event. There is virtually no spending on physical assets, so free cash flow is essentially the same as operating cash flow and firmly negative. Sustainability of the current plan depends on continued access to capital markets, grants, or partners; there is no internal cash generation to support the pipeline.

Competitive Edge

Competitive Edge Annovis competes in one of the most crowded and high‑stakes areas in biotech: Alzheimer’s and Parkinson’s disease. Its main edge is a distinct scientific approach—using an oral small molecule designed to reduce several toxic proteins at once, rather than targeting just one, as many antibody drugs do. Strong patent coverage into the mid‑2040s and the convenience of a pill support a potential moat if the drug works as hoped. That said, the company is very small versus large pharma players that already have approved Alzheimer’s drugs and much greater commercial and financial resources. Annovis’ competitive position therefore hinges on clearly superior or meaningfully differentiated clinical results to stand out.

Innovation and R&D

Innovation and R&D Innovation is the clear focal point for Annovis. Its lead candidate, buntanetap, is designed to intervene early in the disease process by limiting production of multiple harmful proteins linked to Alzheimer’s, Parkinson’s, and related conditions, and it is taken orally, which is patient‑friendly. The company is pushing this drug through late‑stage trials in Alzheimer’s and has generated encouraging signals in Parkinson’s, while also exploring combinations with other therapies to boost cognitive benefits. Earlier‑stage programs for acute brain injury and advanced dementia, some supported by government grants, broaden the platform but are still at an early stage. Overall, R&D is high‑risk but conceptually ambitious, with upcoming trial readouts and regulatory discussions as critical proof points.

Summary

Annovis Bio is a classic high‑risk, high‑uncertainty clinical‑stage biotech: no revenue, ongoing losses, and a small but debt‑free balance sheet that relies on external funding. Its value proposition rests almost entirely on the success of its lead drug, which uses a differentiated, multi‑target approach to neurodegenerative diseases and benefits from long‑dated patent protection and oral dosing. The scientific story is compelling but unproven at commercial scale, and the company faces formidable competition from much larger players in Alzheimer’s and Parkinson’s. Future outcomes will be driven less by current financials and more by clinical trial results, regulatory feedback, and the company’s ability to keep funding its R&D without over‑stretching its limited capital base.

NEWS

November 24, 2025 · 8:00 AM UTC

Annovis Announces Two Presentations at the CTAD 2025 Conference

Read more

November 18, 2025 · 8:00 AM UTC

Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study

Read more

November 17, 2025 · 8:00 AM UTC

Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

Read more

November 12, 2025 · 8:00 AM UTC

Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

Read more

November 6, 2025 · 8:00 AM UTC

Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer's Program

Read more